24-hour control of intraocular pressure with 2% dorzolamide/0.5% timolol fixed-combination ophthalmic solution in open-angle glaucoma

Current Medical Research and Opinion

Volumn 24, Issue 8, 2008, Pages 2403-2412

  Feldman, Robert M ^a   Stewart, Robert H ^b   Stewart, William C ^c,d   Jia, Gang ^e   Smugar, Steven S ^e   Galet, Vincent A ^e  

^a UNIVERSITY OF TEXAS   (United States)

^b Houston Eye Associates   (United States)

^c UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d University of South Carolina   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Diurnal rhythm; Dorzolamide; Glaucoma; Ocular hypertension; Timolol

Indexed keywords

DORZOLAMIDE PLUS TIMOLOL; TIMOLOL MALEATE;

ADULT; AGED; BLURRED VISION; CHOLELITHIASIS; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONSCIOUSNESS DISORDER; CONTROLLED STUDY; DIABETIC NEUROPATHY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; EVENING DOSAGE; EYE DISEASE; EYE IRRITATION; EYE PAIN; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; OPEN ANGLE GLAUCOMA; PAPILLEDEMA; PATIENT COMPLIANCE; PATIENT MONITORING; PRESSURE MEASUREMENT; RANDOMIZED CONTROLLED TRIAL; RETINA EXUDATE; REVIEW; URINARY TRACT INFECTION; VITREOUS FLOATERS;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; CARBONIC ANHYDRASE INHIBITORS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; SULFONAMIDES; THIOPHENES; TIMOLOL;

EID: 50149087896     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007990802243366     Document Type: Review

References (40)

1. Stewart WC, Kolker AE, Sharpe ED, et al. Factors associated with long-term progression or stability in primary open-angle glaucoma. Am J Ophthalmol 2000;130:274-9
2. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma & patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol 1998;126:487-97
3. Nouri-Mahdavi K, Hoffman D, Coleman AL, et al. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology 2004;111:1627-35
4. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701-13
5. Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001;108:1943-53
6. Nasser OJ, Stewart WC. Glaucoma treatment and diagnostic trends. Review of Ophthalmology 2006. Available at http://www.revophth.com/ index.asp?page=1_908.htm [Last accessed 4 April 2008]
7. Konstas AG, Lake S, Economou AI, et al. 24-Hour control with a latanoprost-timolol fixed combination vs timolol alone. Arch Ophthalmol 2006;124:1553-7
8. Konstas AG, Kozobolis VP, Katsimpris IE, et al. Efficacy and safety of latanoprost versus travoprost in exfoliative glaucoma patients. Ophthalmology 2007;114:653-7
9. Konstas AG, Mikropoulos D, Kaltsos K, et al. 24-hour intraocular pressure control obtained with evening- versus morning-dosed travoprost in primary open-angle glaucoma. Ophthalmology 2006;113:446-50
10. Denis P, Andrew R, Wells D, et al. A comparison of morning and evening instillation of a combination travoprost 0.004%/timolol 0.5% ophthalmic solution. Eur J Ophthalmol 2006;16: 407-15
11. Orzalesi N, Rossetti L, Bottoli A, et al. The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Arch Ophthalmol 2003;121:453-7
12. Konstas AG, Papapanos P, Tersis I, et al. Twenty-four-hour diurnal curve comparison of commercially available latanoprost 0.005% versus the timolol and dorzolamide fixed combination. Ophthalmology 2003;110:1357-60
13. Hughes E, Spry P, Diamond J. 24-hour monitoring of intraocular pressure in glaucoma management: a retrospective review. J Glaucoma 2003;12:232-6
14. Mosaed S, Liu JH, Weinreb RN. Correlation between office and peak nocturnal intraocular pressures in healthy subjects and glaucoma patients. Am J Ophthalmol 2005;139:320-4
15. Barkana Y, Anis S, Liebmann J, et al. Clinical utility of intraocular pressure monitoring outside of normal office hours in patients with glaucoma. Arch Ophthalmol 2006;124:793-7
16. Asrani S, Zeimer R, Wilensky J, et al. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma 2000;9:134-42
17. Hara T, Hara T, Tsuru T. Increase of peak intraocular pressure during sleep in reproduced diurnal changes by posture. Arch Ophthalmol 2006;124:165-8
18. Orzalesi N, Rossetti L, Invernizzi T, et al. Effect of timolol, latanoprost: and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci 2000; 41:2566-73
19. Orzalesi N, Rossetti L, Bottoli A, et al. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Ophthalmology 2006;113:239-46
20. Mishima HK, Kiuchi Y, Takamatsu M, et al. Circadian intraocular pressure management with latanoprost: diurnal and nocturnal intraocular pressure reduction and increased uveoscleral outflow. Surv Ophthalmol 1997;41(Suppl 2) S139-44:S139-144
21. Racz P, Ruzsonyi MR, Nagy ZT, et al. Around-the-clock intraocular pressure reduction with once-daily application of latanoprost by itself or in combination with timolol. Arch Ophthalmol 1996;114:268-73
22. Kida T, Liu JH, Weinreb RN. Effect of 24-hour corneal biomechanical changes on intraocular pressure measurement. Invest Ophthalmol Vis Sci 2006;47:4422-6
23. Liu JH, Kripke DF, Twa MD, et al. Twenty-four-hour pattern of intraocular pressure in the aging population. Invest Ophthalmol Vis Sci 1999;40:2912-7
24. Weinreb RN, Liu JH. Nocturnal rhythms of intraocular pressure. Arch Ophthalmol 2006;124:269-70
25. Hutzelmann J, Owens S, Shedden A, et al. Comparison of the safety and efficacy of the fixed combination of dorzolamide/timolol and the concomitant administration of dorzolamide and timolol: a clinical equivalence study. International Clinical Equivalence Study Group. Br J Ophthalmol 1998;82:1249-53
26. Boyle JE, Ghosh K, Gieser DK, et al. A randomized trial comparin the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzolamide-Timolol Study Group. Ophthalmology 1998;105:1945-51
27. Clineschmidt CM, Williams RD, Snyder E, et al. A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. Dorzolamide-Timolol Combination Study Group. Ophthalmology 1998;105:1952-9
28. Adamsons I, Clineschmidt C, Polis A, et al. The efficacy and safety of dorzolamide as adjunctive therapy to timolol maleate gellan solution in patients with elevated intraocular pressure. Additivity Study Group. J Glaucoma 1998;7:253-60
29. Harris A, Jonescu-Cuypers CP, Kagemann L, et al. Effect of dorzolamide timolol combination versus timolol 0.5% on ocular bloodflow in patients with primary open-angle glaucoma. Am J Ophthalmol 2001;132:490-5
30. Francis BA, Du LT, Berke S, et al. Comparing the fixed combination dorzolamide-timolol (Cosopt) to concomitant administration of 2% dorzolamide (Trusopt) and 0.5% timolol - a randomized controlled trial and a replacement study. J Clin Pharm Ther 2004;29:375-80
31. Strohmaier K, Snyder E, DuBiner H, et al. The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Dorzolamide-Timolol Study Group. Ophthalmology 1998;105:1936-44
32. Topper JE, Brubaker RF. Effects of timolol, epinephrine, and acetazolamide on aqueous flow during sleep. Invest Ophthalmol Vis Sci 1985;26:1315-19
33. Liu JH, Kripke DF, Weinreb RN. Comparison of the nocturnal effects of once-daily timolol and latanoprost on intraocular pressure. Am J Ophthalmol 2004;138:389-95
34. Konstas AG, Maltezos AC, Gandi S, et at. Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma. Am J Ophthalmol 1999; 128:15-20
35. Quaranta L, Gandolfo F, Turano R, et al. Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma. Invest Ophthalmol Vis Sci 2006;47:2917-23
36. Konstas AG, Boboridis K, Tzetzi D, et al. Twenty-four-hour control with latanoprost-timolol-fixed combination therapy vs latanoprost therapy. Arch Ophthalmol 2005; 123:898-902
37. Konstas AG, Maltezos A, Bufidis T, et al. Twenty-four hour control of intraocular pressure with dorzolamide and timolol maleate in exfoliation and primary open-angle glaucoma. Eye 2000;14:73-7
38. Vanlandingham BD, Maus TL, Brubaker RF. The effect of dorzolamide on aqueous humor dynamics in normal human subjects during sleep. Ophthalmology 1998;105:1537-40
39. Ingram CJ, Brubaker RF. Effect of brinzolamide and dorzolamide on aqueous humor flow in human eyes. Am J Ophthalmol 1999;128:292-6
40. Brubaker RF. Flow of aqueous humor in humans [The Friedenwald Lecture]. Invest Ophthalmol Vis Sci 1991; 32:3145-66